Portal de investigación
Desarrollo de nuevos fármacos “multidiana” en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular associada.
Datos básicos
- Protocolo:
- APOTIP/2020/011
- EUDRACT:
- NCT:
- Centro:
- INCLIVA
- Año de incio:
- Año de finalización:
- 2022
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO
Resultados del Ensayo Clínico
Anti-inflammatory effects and improved metabolic derangements in ob/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity
Marques, Patrice; (...); Cabedo, Nuria
Article. 10.1016/j.phrs.2022.106638. 2023
Benzopyran hydrazones with dual PPARa/? or PPARa/d agonism and an anti-inflammatory effect on human THP-1 macrophages.
Article. 10.1016/j.ejmech.2024.116125. 2024
Synthesis and biological studies of "Polycerasoidol" and "trans-d-Tocotrienolic acid" derivatives as PPARa and/or PPAR? agonists.
Vila, Laura; (...); Cortes, Diego
Article. 10.1016/j.bmc.2021.116532. 2022
Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer
Article. 10.1039/d3md00385j. 2023
Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPARa/? Agonist Activity.
Garcia, A; (...); Cortes, D
Article. 10.1021/acsmedchemlett.1c00400. 2021
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Article. 10.1016/j.phrs.2024.107058. 2024
